Reuters.LEVERKUSEN – Bayer AG (ETR:) has ceased its phase III asundexian trial early based on the recommendation from the Independent Data Monitoring Committee (IDMC). The IDMC concluded that asundexian was less effective than apixaban, a current standard treatment, in preventing strokes in patients with atrial fibrillation at risk of stroke. This decision was announced today.
The OCEANIC-AF trial, which began in August 2022, aimed to evaluate the efficacy of asundexian but faced an early termination due to its comparative lesser effectiveness. Despite this setback, Bayer (OTC:) remains committed to its OCEANIC-STROKE trial, which targets patients with limited treatment options and will proceed as scheduled.
In addition to these clin…
Read the full article at: https://au.investing.com/news/stock-market-news/bayer-halts-asundexian-trial-considers-restructuring-93CH-3042870